MX2022008450A - Anticuerpos anti-gal3 y metodos de uso. - Google Patents
Anticuerpos anti-gal3 y metodos de uso.Info
- Publication number
- MX2022008450A MX2022008450A MX2022008450A MX2022008450A MX2022008450A MX 2022008450 A MX2022008450 A MX 2022008450A MX 2022008450 A MX2022008450 A MX 2022008450A MX 2022008450 A MX2022008450 A MX 2022008450A MX 2022008450 A MX2022008450 A MX 2022008450A
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- fibrosis
- treatment
- disease
- gal3
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C07K2319/43—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation containing a FLAG-tag
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062960300P | 2020-01-13 | 2020-01-13 | |
| US202063024327P | 2020-05-13 | 2020-05-13 | |
| US202063092069P | 2020-10-15 | 2020-10-15 | |
| US202063122409P | 2020-12-07 | 2020-12-07 | |
| PCT/US2021/013136 WO2021146218A1 (en) | 2020-01-13 | 2021-01-12 | Anti-gal3 antibodies and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022008450A true MX2022008450A (es) | 2022-12-13 |
Family
ID=76864188
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022008450A MX2022008450A (es) | 2020-01-13 | 2021-01-12 | Anticuerpos anti-gal3 y metodos de uso. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230036181A1 (https=) |
| EP (1) | EP4090685A4 (https=) |
| JP (2) | JP2023510866A (https=) |
| KR (1) | KR20220129030A (https=) |
| CN (2) | CN119930824A (https=) |
| AU (1) | AU2021207461A1 (https=) |
| BR (1) | BR112022013892A2 (https=) |
| CA (1) | CA3166552A1 (https=) |
| IL (1) | IL294486A (https=) |
| MX (1) | MX2022008450A (https=) |
| WO (1) | WO2021146218A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| JP7835441B2 (ja) * | 2019-12-06 | 2026-03-25 | トゥルーバインディング，インコーポレイテッド | Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法 |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| IL308258A (en) | 2021-05-05 | 2024-01-01 | Immatics Biotechnologies Gmbh | Bma031 antigen binding polypeptides |
| JP2024526764A (ja) * | 2021-07-13 | 2024-07-19 | トゥルーバインディング，インコーポレイテッド | タンパク質凝集を防止する方法 |
| CN118524852A (zh) * | 2021-11-09 | 2024-08-20 | 真和制药有限公司 | 治疗或抑制心血管疾病的方法 |
| WO2024073511A2 (en) * | 2022-09-28 | 2024-04-04 | Truebinding, Inc. | Therapies with anti-gal3 antibodies |
| WO2025185724A1 (en) * | 2024-03-08 | 2025-09-12 | Sunmed Therapeutic Limited | Anti-galectin 3 antibodies and their use in epilepsy and related diseases |
| CN118286392A (zh) * | 2024-03-28 | 2024-07-05 | 广州医科大学附属妇女儿童医疗中心 | 重组Galectin-3在治疗慢性炎性脱髓鞘性多发性神经根神经病中的应用 |
| WO2025240949A1 (en) * | 2024-05-17 | 2025-11-20 | The Administrators Of The Tulane Educational Fund | Compositions and methods for the treatment of idiopathic pulmonary fibrosis |
| WO2025264872A1 (en) * | 2024-06-21 | 2025-12-26 | Truebinding, Inc. | Methods and compositions for treating neurodevelopmental disorders |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4792390B2 (ja) * | 2004-03-29 | 2011-10-12 | 株式会社ガルファーマ | 新規ガレクチン９改変体タンパク質及びその用途 |
| GB0624500D0 (en) * | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| UA104132C2 (en) * | 2007-11-13 | 2014-01-10 | Тева Биофармасьютикалз Юесей, Инк. | Humanized antibodies against tl1a |
| US8349579B2 (en) * | 2007-12-13 | 2013-01-08 | Wayne State University | Galectin-3 cleavage as a marker for matrix metalloproteinase activity in cancer |
| AU2009340423B2 (en) * | 2008-10-29 | 2014-07-24 | Bg Medicine, Inc. | Galectin-3 immunoassay |
| CA2818173C (en) * | 2010-11-30 | 2022-05-03 | Genentech, Inc. | Low affinity blood brain barrier receptor antibodies and uses therefor |
| BR112016013876B1 (pt) * | 2013-12-27 | 2022-03-22 | Eliaz Therapeutics, Inc. | Dispositivo para realização de plasmaferese |
| WO2016004093A2 (en) * | 2014-07-01 | 2016-01-07 | Stealth Biotherapeutics Corp | Therapeutic compositions including galectin-3 inhibitors and uses thereof |
| CA2874083C (en) * | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| CN111201030B (zh) * | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| AU2019215202B2 (en) * | 2018-02-01 | 2025-11-13 | Memorial Sloan Kettering Cancer Center | Antibodies to Galectin-3 and methods of use thereof |
| EP3759145A4 (en) * | 2018-02-26 | 2022-03-09 | Minerva Biotechnologies Corporation | DIAGNOSTIC METHODS USING ANTI-MUC1* ANTIBODIES |
| WO2020160156A2 (en) * | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
-
2021
- 2021-01-12 BR BR112022013892A patent/BR112022013892A2/pt unknown
- 2021-01-12 EP EP21741281.6A patent/EP4090685A4/en active Pending
- 2021-01-12 MX MX2022008450A patent/MX2022008450A/es unknown
- 2021-01-12 KR KR1020227028093A patent/KR20220129030A/ko active Pending
- 2021-01-12 CA CA3166552A patent/CA3166552A1/en active Pending
- 2021-01-12 JP JP2022542784A patent/JP2023510866A/ja active Pending
- 2021-01-12 CN CN202510130333.4A patent/CN119930824A/zh active Pending
- 2021-01-12 IL IL294486A patent/IL294486A/en unknown
- 2021-01-12 CN CN202180022171.2A patent/CN115427449A/zh active Pending
- 2021-01-12 AU AU2021207461A patent/AU2021207461A1/en active Pending
- 2021-01-12 WO PCT/US2021/013136 patent/WO2021146218A1/en not_active Ceased
-
2022
- 2022-07-12 US US17/812,159 patent/US20230036181A1/en not_active Abandoned
-
2025
- 2025-01-10 US US19/017,208 patent/US20250145722A1/en active Pending
- 2025-07-22 JP JP2025122880A patent/JP2025163070A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023510866A (ja) | 2023-03-15 |
| CA3166552A1 (en) | 2021-07-22 |
| CN115427449A (zh) | 2022-12-02 |
| EP4090685A1 (en) | 2022-11-23 |
| EP4090685A4 (en) | 2024-12-18 |
| BR112022013892A2 (pt) | 2022-10-04 |
| US20250145722A1 (en) | 2025-05-08 |
| US20230036181A1 (en) | 2023-02-02 |
| IL294486A (en) | 2022-09-01 |
| KR20220129030A (ko) | 2022-09-22 |
| CN119930824A (zh) | 2025-05-06 |
| JP2025163070A (ja) | 2025-10-28 |
| WO2021146218A1 (en) | 2021-07-22 |
| AU2021207461A1 (en) | 2022-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022008450A (es) | Anticuerpos anti-gal3 y metodos de uso. | |
| Curtin et al. | Therapeutic applications of PARP inhibitors: anticancer therapy and beyond | |
| AU2018236742B2 (en) | Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same | |
| MX358321B (es) | Anticuerpos anti-ceacam5 y usos de los mismos. | |
| CO2017001921A2 (es) | Anticuerpos anti-cll-1 e inmunoconjugados | |
| CL2011003052A1 (es) | Compuesto 8-(2,4-dimetoxi-pirimidin-5-il)-1-(1-etil-3-metil-1h-pirazol-4-il)-3-metil-1,3-dihidro-imidazo[4,5-c]quinolin-2-ona; su composicion farmaceutica; util en el tratamiento de enfermedades dependientes de la cinasa de lipido y/o de proteina, en el tratamiento de enfermedades proliferativas, tales como tumores y carcinomas de cerebro, riñon, higado, entre otras. | |
| WO2017177149A3 (en) | Methods and compositions for car t cell therapy | |
| BR112012024564A2 (pt) | anticorpos contra csf-1r | |
| WO2007067992A3 (en) | Human monoclonal antibodies to fucosyl-gm1 and methods for using anti-fucosyl-gm1 | |
| CA2740134C (en) | Formulations targeting igfbp7 for diagnosis and therapy of cancer | |
| WO2006014729A3 (en) | Inhibitors of angiopoietin-like 4 protein, combinations, and their use | |
| MX2015005328A (es) | Composiciones y metodos para la administracion selectiva de moleculas de oligonucleotidos a tipos de celulas. | |
| CR20220136A (es) | Proteínas de fijación multiespecíficas para tratamiento contra el cáncer | |
| WO2014081944A9 (en) | Egfr and c-met-fibronectin type iii domain binding molecules | |
| WO2008106646A3 (en) | Methods and formulations for topical gene therapy | |
| BRPI0410748B8 (pt) | compostos de maitansinóides, suas composições farmacêuticas, métodos de esterificação de maitansinóides, bem como métodos para a sua produção, e conjugado de maitansinóide-agente de ligação celular | |
| AR059982A1 (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| WO2008116157A3 (en) | Mesenchymal stem cells and uses therefor | |
| WO2009073050A3 (en) | Use of curcumin to block brain tumor formation in vivo | |
| WO2005044990A3 (en) | Use of differentially expressed nucleic acid sequences as biomarkers for cancer | |
| MX2020008613A (es) | Conjugados de anticuerpo anti-factor tisular-farmaco y su uso en el tratamiento de cancer. | |
| MX2021008261A (es) | Agentes de rnai para inhibir la expresion de hif-2 a (epas1), composiciones de estos y metodos de uso. | |
| WO2005065361A3 (en) | Compounds and compositions for treating dysproliferative diseases, and methods of use thereof | |
| WO2002053700A3 (en) | Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof | |
| ATE469220T1 (de) | Antikörper, die krebserkrankungen modifizieren |